Sugi Predict

Sugi Predict / Compounds / SCHEMBL480997

SCHEMBL480997

SCHEMBL480997

OC(c1ccccc1)(c1ccccc1)[C@@H](c1ccccc1)N1CCCCC1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 11/20 0.73
▸ KCNH2 Q12809 10/20 0.73
▸ CYP2D6 P10635 8/20 0.58
▸ CYP2C19 P33261 8/20 0.58
▸ CYP3A4 P08684 7/20 0.58
▸ CYP2C9 P11712 6/20 0.58
▸ HTT P42858 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ CYP1A2 P05177 6/20 0.53
▸ KCNE1 P15382 1/20 0.53
▸ GAA P10253 1/20 0.49
▸ LMNA P02545 2/20 0.46
▸ TSHR P16473 2/20 0.45
▸ CHRM2 P08172 1/20 0.44
▸ HTR1A P08908 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ OPRM1 P35372 1/20 0.44
▸ HPGD P15428 1/20 0.43
▸ MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12587918 1.00 KCNA5 (0.73) KCNA5KCNH2CYP2D6CYP2C19CYP3A4
SCHEMBL480998 1.00 KCNA5 (0.73) KCNA5KCNH2CYP2D6CYP2C19CYP3A4
SCHEMBL5541536 1.00 KCNA5 (0.73) KCNA5KCNH2CYP2D6CYP2C19CYP3A4
SCHEMBL13649151 0.98 KCNA5 (0.73) KCNA5KCNH2CYP2D6CYP2C19CYP3A4
SCHEMBL1243260 0.85 KCNA5 (1.00) KCNA5KCNH2CYP2D6CYP2C19CYP3A4
SCHEMBL10461663 0.85 KCNA5 (0.60) KCNA5KCNH2CYP2D6CYP2C19CYP3A4
SCHEMBL1243557 0.84 KCNA5 (0.64) KCNA5KCNH2CYP2D6CYP2C19CYP3A4
SCHEMBL22046668 0.84 KCNA5 (0.55) KCNA5KCNH2CYP2D6CYP2C19CYP3A4
SCHEMBL1242084 0.83 KCNA5 (1.00) KCNA5KCNH2CYP2D6CYP2C19CYP3A4
SCHEMBL12587920 0.83 KCNA5 (1.00) KCNA5KCNH2CYP2D6CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105884766-B A kind of method for synthesizing minot phosphoric acid intermediate 复旦大学 2017-11-24 — — CN claimed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 — — EP claimed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 — — US claimed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 — — US claimed
EP-1817301-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-15 — — EP claimed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 — — WO claimed
EP-3383844-B1 PROCESS FOR THE PREPARATION OF CARBOPROST AND ITS TROMETHAMINE SALT CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) 2020-06-03 — — EP disclosed
US-10442762-B2 Process for the preparation of carboprost and its tromethamine salt CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA ZRT. (HU) 2019-10-15 — — US disclosed
WO-2017093770-A1 PROCESS FOR THE PREPARATION OF CARBOPROST AND ITS TROMETHAMINE SALT CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) 2017-06-08 — — WO disclosed
CN-103360387-B A kind of method preparing compound zolpidem 江苏豪森药业集团有限公司 2016-12-14 — — CN disclosed
CN-103360387-A Method for preparing compound zolpidem UNIV FUDAN 2013-10-23 — — CN disclosed
EP-2441762-A1 Potentiators of Glutamate Receptors Eli Lilly and Company (US) 2012-04-18 — — EP disclosed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 — — EP disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 — — US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 — — US disclosed
US-20090318483-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 — — US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 — — US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 — — US disclosed
EP-1817301-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-15 — — EP disclosed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139505-A1 Potentiators Of Glutamate Receptors GRM1, GRIN1, GRM2 KCNA5 564/4885KCNH2 536/4885CYP2D6 810/4885
US-20090318481-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 KCNA5 301/4885KCNH2 228/4885CYP2D6 1973/4885
US-10442762-B2 Process for the preparation of carboprost and its tromethamine salt PTGER4, PTGER1, PTGER2 KCNA5 2983/4885KCNH2 3578/4885CYP2D6 802/4885
US-20090318483-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 KCNA5 301/4885KCNH2 228/4885CYP2D6 1973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.